Antengene: Gunning To Move Up in Line
This Insight provides an in-depth review of pre-revenue biotechnology Antegene that plans to list on the HKEX. We discuss the pipeline, market...
463 Views
What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
343 Views
HSCI Index Rebalance - Stock Connect Flows Coming Up
The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....
488 Views
HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities
Hang Seng Indexes Company (HSIL) reviews the constituents of the Hang Seng Composite Index (HSCI) on a half yearly basis in March and September...
769 Views
HK IPO Analytics 1H2020: Highlight of Brokers' and Sectors' Performance, and Insti Book Color
As we regularly analyse deal performance, it is time to look at how the HK IPO markets performed during the first half of 2020. In this note, we...
443 Views